Sample sizes of the initial dataset, and for samples that were able to be included at each stage (mutation burden calling, neoepitope load estimation, and then gene expression analysis), are reported for each of the three breast cancer subtype categories (ER/PR(+)HER-2(−), HER-2(+), TNBC) (PDF 56 kb). This evidence concerns the gene ESR1 and breast cancer.